Effect of Platelet Parameters on Linezolid-Related Thrombocytopenia in Hospitalized Patients

References

• Lazaris A, Coleman DC, Kearns AM, et al. Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE. J Antimicrob Chemother. 2017;72(12):3252–3257. doi:10.1093/jac/dkx292
   PubMed Web of Science ®Google Scholar
• Leach KL, Brickner SJ, Noe MC, et al. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci. 2011;1222(1):49–54. doi:10.1111/j.1749-6632.2011.05962.x
   PubMedGoogle Scholar
• Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029–1035. doi:10.1007/s10096-013-2041-3
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–387. doi:10.1007/s10156-010-0182-1
   PubMed Web of Science ®Google Scholar
• Lee EY, Caffrey AR. Thrombocytopenia with Tedizolid and Linezolid. Antimicrob Agents Chemother. 2018;62. doi:10.1128/AAC.01453-17
   Web of Science ®Google Scholar
• Tsuji Y, Holford NHG, Kasai H, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol. 2017;83:1758–1772. doi:10.1111/bcp.13262
   PubMed Web of Science ®Google Scholar
• Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–2133. doi:10.1093/jac/dkt133
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–2726. doi:10.1128/aac.46.8.2723-2726.2002
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72. doi:10.1086/498509
   PubMed Web of Science ®Google Scholar
• George MR, Creer MH. Advanced platelet parameters: underutilized tools in the diagnosis and management of thrombopoietic states? Transfusion. 2017;57(4):874–875. doi:10.1111/trf.14044
   PubMed Web of Science ®Google Scholar
• Kaito K, Otsubo H, Usui N, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol. 2005;128(5):698–702. doi:10.1111/j.1365-2141.2004.05357.x
   PubMed Web of Science ®Google Scholar
• Numbenjapon T, Mahapo N, Pornvipavee R, et al. A prospective evaluation of normal mean platelet volume in discriminating hyperdestructive thrombocytopenia from hypoproductive thrombocytopenia. Int J Lab Hematol. 2008;30(5):408–414. doi:10.1111/j.1751-553X.2007.00969.x
   PubMed Web of Science ®Google Scholar
• Tang YT, He P, Li YZ, et al. Diagnostic value of platelet indices and bone marrow megakaryocytic parameters in immune thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2017;28(1):83–90. doi:10.1097/mbc.0000000000000612
   PubMed Web of Science ®Google Scholar
• Negash M, Tsegaye A. Diagnostic predictive value of platelet indices for discriminating hypo productive versus immune thrombocytopenia purpura in patients attending a tertiary care teaching hospital in Addis Ababa, Ethiopia. BMC Hematol. 2016;16(1):18. doi:10.1186/s12878-016-0057-5
   PubMedGoogle Scholar
• Chen C, Guo DH, Cao X, et al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195–206. doi:10.1016/j.curtheres.2012.07.002
   PubMed Web of Science ®Google Scholar
• Hirano R, Sakamoto Y, Tachibana N, et al. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36(4):795–799. doi:10.1007/s11096-014-9961-6
   PubMed Web of Science ®Google Scholar
• Yang J, Zhou X, Fan X, et al. mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation. Blood. 2016;128(5):615–624. doi:10.1182/blood-2015-10-672964
   PubMed Web of Science ®Google Scholar
• Zhang XH, Wang QM, Zhang JM, et al. Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. J Hematol Oncol. 2015;8:116. doi:10.1186/s13045-015-0216-3
   PubMed Web of Science ®Google Scholar
• Li MF, Li XL, Fan KL, et al. Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial. J Hematol Oncol. 2017;10:104. doi:10.1186/s13045-017-0476-1
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Yilmaz A. Relationship between Altered Platelet Morphological Parameters and Retinopathy in Patients with Type 2 Diabetes Mellitus. J Ophthalmol. 2016;2016:9213623. doi:10.1155/2016/9213623
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Santagostino E. Platelets: much more than bricks in a breached wall. Br J Haematol. 2017;178(2):209–219. doi:10.1111/bjh.14653
   PubMed Web of Science ®Google Scholar
• Machlus KR, Italiano JE. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201(6):785–796. doi:10.1083/jcb.201304054
   PubMed Web of Science ®Google Scholar
• Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58(4):2334–2343. doi:10.1128/AAC.01885-13
   PubMed Web of Science ®Google Scholar
• Natsumoto B, Yokota K, Omata F, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007–1012. doi:10.1007/s15010-014-0674-5
   PubMed Web of Science ®Google Scholar
• Zhang YM, Yu W, Zhou N, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int. 2015;14(3):287–292. doi:10.1016/S1499-3872(15)60379-4
   PubMed Web of Science ®Google Scholar
• Choi GW, Lee JY, Chang MJ, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228–234. doi:10.1111/bcpt.13123
   PubMed Web of Science ®Google Scholar
• Waki F, Ohnishi H, Shintani T, et al. Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2012;14(4):E1–6. doi:10.1111/j.1399-3062.2012.00728.x
   PubMed Web of Science ®Google Scholar
• Ebeling F, Helminen P, Anttila VJ. Appearance of ring sideroblasts in bone marrow during linezolid therapy. Scand J Infect Dis. 2009;41(6–7):480–482. doi:10.1080/00365540902971203
   PubMed Web of Science ®Google Scholar
• Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517–520. doi:10.1345/aph.1C361
   PubMed Web of Science ®Google Scholar
• Cojutti P, Maximova N, Crichiutti G, et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother. 2015;70(1):198–206. doi:10.1093/jac/dku337
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242–247. doi:10.1016/j.ijantimicag.2014.05.010
   PubMed Web of Science ®Google Scholar
• Lynch J, Wong-Beringer A. Caspofungin: a potential cause of reversible severe thrombocytopenia. Pharmacotherapy. 2004;24(10):1408–1411. doi:10.1592/phco.24.14.1408.43148
   PubMed Web of Science ®Google Scholar
• Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536–542. doi:10.1016/j.jiac.2016.05.003
   PubMed Web of Science ®Google Scholar
• Taubert M, Zoller M, Maier B, et al. Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients. Antimicrob Agents Chemother. 2016;60(9):5254–5261. doi:10.1128/AAC.00356-16
   PubMed Web of Science ®Google Scholar
• Zuo M, Sun Y, Zhao X, et al. Evaluating linezolid dose regimens against methicillin-resistant Staphylococcus aureus based on renal function in populations with different body weight. J Clin Pharm Ther. 2022;30.
   Web of Science ®Google Scholar
• Thiery-Antier N, Binquet C, Vinault S, et al. Is Thrombocytopenia an Early Prognostic Marker in Septic Shock? Crit Care Med. 2016;44(4):764–772. doi:10.1097/ccm.0000000000001520
   PubMed Web of Science ®Google Scholar
• Mauro P, Andrea A, Passamontiserena M, et al. Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. Minerva Anestesiol. 2016;82(2):170–179.
   PubMed Web of Science ®Google Scholar
• Guru Pramod K, Singh Tarun D, Akhoundi A, et al. Association of thrombocytopenia and mortality in critically ill patients on continuous renal replacement therapy. Nephron. 2016;133(3):175–182. doi:10.1159/000447543
   PubMed Web of Science ®Google Scholar
• Rong-Hui D, Li-Rong L, Cheng-Qing Y, et al. Predictors of mortality for patients with severe coronavirus disease infections: a prospective cohort study. Eur Respir J. 2020;55(5). doi:10.1183/13993003.00524-2020
   Web of Science ®Google Scholar
• Samad G, Nashmil P, Leili P, et al. Prognostic value of platelet indices in patients with acute pulmonary thromboembolism. J Cardiovasc Thorac Res. 2020;12(1):56–62. doi:10.34172/jcvtr.2020.09
   PubMed Web of Science ®Google Scholar
• Ostovan MA, Ghaffari S, Pourafkari L, et al. Modification of simplified pulmonary embolism severity index and its prognostic value in patients with acute pulmonary embolism. Heart Lung Circ. 2016;25(2):184–190. doi:10.1016/j.hlc.2015.08.008
   PubMed Web of Science ®Google Scholar